The changes of the indications and the use of hormone replacement therapy have entered into the focus of interest.
The author studied whether hormone replacement therapy can be used in postmenopausal patients with high risk factors in their history (thromboembolic disorders, diabetes mellitus, hypertension, stroke, cardiovascular disease, pulmonary embolism).
Tibolone 2.5 mg daily was prescribed. Data of 124 patients with the above conditions were analized at the beginning and at 12, 24, 36 months follow-up visits. The frequency of exacerbation of the anamnestic risk factors, menopausal complaints, laboratory tests and instrumental tests (transvaginal sonography, mammography, bone densitometry), as well as efficacy and side effects of the therapy were studied.
During the 36-months follow up tibolone therapy effectively reduced menopausal complaints, caused no increase in the anamnestic risk factors, or serious side effects and did not worsened the results of the laboratory tests.
In the author's opinion hormone replacement therapy with tibolone can be safely performed in patients with high risk factors in the history.